Business Description
Lumosa Therapeutics Co Ltd
ISIN : TW0006535008
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 57.76 | |||||
Equity-to-Asset | 0.86 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.04 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 150.2 | |||||
Beneish M-Score | -2.73 | |||||
WACC vs ROIC |
Growth Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 25 | |||||
3-Year EBITDA Growth Rate | 16.2 | |||||
3-Year EPS without NRI Growth Rate | 18.1 | |||||
3-Year FCF Growth Rate | -25.3 | |||||
3-Year Book Growth Rate | -7.4 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 58.25 | |||||
9-Day RSI | 66.22 | |||||
14-Day RSI | 67.3 | |||||
6-1 Month Momentum % | 24.31 | |||||
12-1 Month Momentum % | 316.11 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.09 | |||||
Quick Ratio | 3.57 | |||||
Cash Ratio | 3.09 | |||||
Days Inventory | 2986.38 | |||||
Days Sales Outstanding | 85.41 | |||||
Days Payable | 10.74 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.7 | |||||
Shareholder Yield % | -0.01 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 73.61 | |||||
Operating Margin % | -730.46 | |||||
Net Margin % | -588.35 | |||||
FCF Margin % | -594.2 | |||||
ROE % | -19.5 | |||||
ROA % | -16.78 | |||||
ROIC % | -42.02 | |||||
ROC (Joel Greenblatt) % | -1189.63 | |||||
ROCE % | -19.91 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 1061.64 | |||||
PB Ratio | 37.46 | |||||
Price-to-Tangible-Book | 37.48 | |||||
EV-to-EBIT | -172.63 | |||||
EV-to-EBITDA | -182.91 | |||||
EV-to-Revenue | 1061.45 | |||||
EV-to-FCF | -179.51 | |||||
Price-to-Net-Current-Asset-Value | 88.32 | |||||
Price-to-Net-Cash | 134.2 | |||||
Earnings Yield (Greenblatt) % | -0.58 | |||||
FCF Yield % | -0.55 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Lumosa Therapeutics Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil NT$) | 47.713 | ||
EPS (TTM) (NT$) | -1.735 | ||
Beta | 0.86 | ||
Volatility % | 112.46 | ||
14-Day RSI | 67.3 | ||
14-Day ATR (NT$) | 13.726791 | ||
20-Day SMA (NT$) | 278.502607 | ||
12-1 Month Momentum % | 316.11 | ||
52-Week Range (NT$) | 58.568535 - 337 | ||
Shares Outstanding (Mil) | 165.3 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Lumosa Therapeutics Co Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Lumosa Therapeutics Co Ltd Stock Events
Event | Date | Price(NT$) | ||
---|---|---|---|---|
No Event Data |
Lumosa Therapeutics Co Ltd Frequently Asked Questions
What is Lumosa Therapeutics Co Ltd(ROCO:6535)'s stock price today?
When is next earnings date of Lumosa Therapeutics Co Ltd(ROCO:6535)?
Does Lumosa Therapeutics Co Ltd(ROCO:6535) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |